title: Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI.
abstract: The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.
authors.affiliation: UMR892-INSERM 6299-CNRS; Université de Nantes; Équipe Cytokines et Récepteurs en Immuno-Cancérologie; Nantes, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Vincent
authors.affiliation: UMR892-INSERM 6299-CNRS; Université de Nantes; Équipe Cytokines et Récepteurs en Immuno-Cancérologie; Nantes, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Quéméner
authors.affiliation: UMR892-INSERM 6299-CNRS; Université de Nantes; Équipe Cytokines et Récepteurs en Immuno-Cancérologie; Nantes, France.
authors.forename: Yannick
authors.initials: Y
authors.lastname: Jacques
keywords: GD2 disialoganglioside; RLI superagonist; cancer therapy; immunocytokine; interleukin-15